JP2023529926A5 - - Google Patents

Info

Publication number
JP2023529926A5
JP2023529926A5 JP2022576040A JP2022576040A JP2023529926A5 JP 2023529926 A5 JP2023529926 A5 JP 2023529926A5 JP 2022576040 A JP2022576040 A JP 2022576040A JP 2022576040 A JP2022576040 A JP 2022576040A JP 2023529926 A5 JP2023529926 A5 JP 2023529926A5
Authority
JP
Japan
Prior art keywords
alkyl
group
optionally substituted
groups
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022576040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529926A (ja
Filing date
Publication date
Priority claimed from GBGB2008749.0A external-priority patent/GB202008749D0/en
Application filed filed Critical
Publication of JP2023529926A publication Critical patent/JP2023529926A/ja
Publication of JP2023529926A5 publication Critical patent/JP2023529926A5/ja
Pending legal-status Critical Current

Links

JP2022576040A 2020-06-09 2021-06-09 Gcn2阻害剤として有用な4-エチニルピリジン誘導体 Pending JP2023529926A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2008749.0A GB202008749D0 (en) 2020-06-09 2020-06-09 Novel compounds
GB2008749.0 2020-06-09
PCT/GB2021/051428 WO2021250399A1 (en) 2020-06-09 2021-06-09 4-ethynylpyridine derivatives useful as gcn2 inhibitors

Publications (2)

Publication Number Publication Date
JP2023529926A JP2023529926A (ja) 2023-07-12
JP2023529926A5 true JP2023529926A5 (cg-RX-API-DMAC7.html) 2025-12-04

Family

ID=71616023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022576040A Pending JP2023529926A (ja) 2020-06-09 2021-06-09 Gcn2阻害剤として有用な4-エチニルピリジン誘導体

Country Status (12)

Country Link
US (2) US20230271939A1 (cg-RX-API-DMAC7.html)
EP (1) EP4161915A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023529926A (cg-RX-API-DMAC7.html)
KR (1) KR20230058042A (cg-RX-API-DMAC7.html)
CN (2) CN116113629B (cg-RX-API-DMAC7.html)
AU (1) AU2021289535A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025147A2 (cg-RX-API-DMAC7.html)
CA (1) CA3181909A1 (cg-RX-API-DMAC7.html)
GB (1) GB202008749D0 (cg-RX-API-DMAC7.html)
IL (1) IL298860B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022015516A (cg-RX-API-DMAC7.html)
WO (1) WO2021250399A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202008749D0 (en) 2020-06-09 2020-07-22 Ip2Ipo Innovations Ltd Novel compounds
GB202104635D0 (en) 2021-03-31 2021-05-12 Imperial College Innovations Ltd Methods and compositions for identifying and treating GCN2-dependent cancers
GB202118096D0 (en) * 2021-12-14 2022-01-26 Ip2Ipo Innovations Ltd Novel compounds
GB202403113D0 (en) 2024-03-04 2024-04-17 Apollo Ap30 Ltd Novel compounds

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037927B2 (en) 2003-10-16 2006-05-02 Abbott Laboratories Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2006082371A1 (en) 2005-02-01 2006-08-10 Astrazeneca Ab Pyrimidine compounds having tie2 (tek) inhibitory activity
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
EP3045457B1 (en) 2009-06-15 2018-05-09 Nerviano Medical Sciences S.r.l. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
US9409914B2 (en) 2012-01-28 2016-08-09 Merck Patent Gmbh Triazolo[4,5-d]pyrimidine derivatives
EP2822948B1 (en) 2012-03-07 2016-04-06 Merck Patent GmbH Triazolopyrazine derivatives
WO2014031928A2 (en) 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
EP2917214B1 (en) 2012-11-07 2019-08-28 Nerviano Medical Sciences S.r.l. Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
CA2903903C (en) 2013-03-05 2021-05-04 Merck Patent Gmbh Triazolo[4,5-d]pyrimidine derivatives for the treatment of diseases such as cancer
EP2964648B1 (en) 2013-03-05 2016-11-16 Merck Patent GmbH 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
CN105732614B (zh) 2014-12-09 2018-06-12 中国科学院广州生物医药与健康研究院 磺酰胺基芳基炔类化合物及其用途
CN104829613B (zh) 2015-04-13 2020-06-09 赤峰蒙广生物科技有限公司 二芳基取代的吡唑并环类衍生物、其制备方法及其在医药领域的应用
PL3498693T3 (pl) * 2016-08-10 2025-03-24 Takeda Pharmaceutical Company Limited Związek heterocykliczny
WO2018068739A1 (zh) 2016-10-13 2018-04-19 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基杂环类化合物
CA3089762A1 (en) 2018-01-29 2019-08-01 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
AU2019212969B2 (en) * 2018-01-29 2025-01-23 Merck Patent Gmbh GCN2 inhibitors and uses thereof
EP3802544A1 (en) 2018-06-05 2021-04-14 RAPT Therapeutics, Inc. Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
WO2020210828A1 (en) * 2019-04-12 2020-10-15 Hibercell, Inc. (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions
US20230128972A1 (en) 2020-01-31 2023-04-27 Atomwise Inc. Anat Inhibitors and Methods of Use Thereof
EP4107146A1 (en) 2020-02-17 2022-12-28 Alesta Therapeutics BV Gcn2 modulator compounds
WO2021222147A1 (en) 2020-04-27 2021-11-04 Hibercell, Inc. Heterocyclic gcn2 modulators
GB202008749D0 (en) 2020-06-09 2020-07-22 Ip2Ipo Innovations Ltd Novel compounds
PE20231311A1 (es) 2020-11-18 2023-08-24 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos
KR20240021143A (ko) 2021-01-22 2024-02-16 히버셀, 인크. Gcn2 조정 화합물 및 그의 용도
US20240150345A1 (en) 2021-01-22 2024-05-09 Hibercell, Inc. Gcn2 modulating compounds and uses thereof

Similar Documents

Publication Publication Date Title
DK2719699T3 (en) Triazolopyraziner particular, compositions thereof and methods of use thereof
ES2747249T3 (es) Derivados de 1-(5-(terc-butil)isoxazol-3-il)-3-(4-((fenil)etinil)fenil)urea y compuestos relacionados como inhibidores de FLT3 para el tratamiento de cáncer
ES2793239T3 (es) Inhibidores del bromodominio
JP2022527796A5 (cg-RX-API-DMAC7.html)
ES2392489T3 (es) Dicarbazoles y procedimientos de uso
CN104513252B (zh) 取代脲衍生物及其在药物中的应用
AU2019392232A1 (en) RET inhibitors, pharmaceutical compositions and uses thereof
JP7702057B2 (ja) がんの治療のためのホスホイノシチド3-キナーゼ(pi3k)のアロステリッククロメノン阻害剤
RU2014130125A (ru) Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их
AU2009259867A1 (en) Triazolopyridine JAK inhibitor compounds and methods
CN102399233A (zh) PI3K和mTOR双重抑制剂类化合物
CN111320624B (zh) 三唑并吡啶类和咪唑并吡啶类化合物及其制备方法和医药用途
TW202229282A (zh) 治療癌症之方法
KR20250004897A (ko) 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제
AU2021204704B2 (en) Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer
RU2008130458A (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-c]ПИРИДИН-4-ОН 2-ИНДОЛИНОНА В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗЫ
CN116283916A (zh) 具有Axl与c-Met激酶抑制活性的化合物及其制备和应用
CN104513258B (zh) 取代脲衍生物及其在药物中的应用
TW202131917A (zh) 併用醫藥
WO2019104067A1 (en) Co-therapies including a metastasis inhibitor
CN117800964A (zh) PI3K/m-TOR抑制剂及其应用
CN105461709B (zh) 取代脲衍生物及其在药物中的应用
CN118894860A (zh) 取代的杂环化合物
WO2025165835A1 (en) Anilino tricyclic compounds, and compositions and methods thereof
TWI690533B (zh) Cdk類小分子抑制劑的化合物及其用途